REMICADE®
(infliximab)
for IV Injection

WARNING

RISK OF INFECTIONS

TUBERCULOSIS (FREQUENTLY DISSEMINATED OR EXTRAPULMONARY AT CLINICAL PRESENTATION), INVASIVE FUNGAL INFECTIONS, AND OTHER OPPORTUNISTIC INFECTIONS, HAVE BEEN OBSERVED IN PATIENTS RECEIVING REMICADE. SOME OF THESE INFECTIONS HAVE BEEN FATAL (SEE WARNINGS). ANTI-TUBERCULOSIS TREATMENT OF PATIENTS WITH A REACTIVE TUBERCULIN SKIN TEST REDUCES THE RISK OF TB REACTIVATION IN PATIENTS RECEIVING TREATMENT WITH REMICADE. HOWEVER, ACTIVE TUBERCULOSIS HAS DEVELOPED IN PATIENTS RECEIVING REMICADE WHO WERE TUBERCULIN SKIN TEST NEGATIVE PRIOR TO RECEIVING REMICADE.

PATIENTS SHOULD BE EVALUATED FOR LATENT TUBERCULOSIS INFECTION WITH A TUBERCULIN SKIN TEST.¹ TREATMENT OF LATENT TUBERCULOSIS INFECTION SHOULD BE INITIATED PRIOR TO THERAPY WITH REMICADE. PHYSICIANS SHOULD MONITOR PATIENTS RECEIVING REMICADE FOR SIGNS AND SYMPTOMS OF ACTIVE TUBERCULOSIS, INCLUDING PATIENTS WHO ARE TUBERCULIN SKIN TEST NEGATIVE.

DESCRIPTION

REMICADE® is a chimeric IgG1κ monoclonal antibody with an approximate molecular weight of 149,100 daltons. It is composed of human constant and murine variable regions. Infliximab binds specifically to human tumor necrosis factor alpha (TNFα) with an association constant of $10^{10}$ M$^{-1}$. Infliximab is produced by a recombinant cell line cultured by continuous perfusion and is purified by a series of steps that includes measures to inactivate and remove viruses.

REMICADE is supplied as a sterile, white, lyophilized powder for intravenous infusion. Following reconstitution with 10 mL of Sterile Water for Injection, USP, the resulting pH is approximately 7.2. Each single-use vial contains 100 mg infliximab, 500 mg sucrose, 0.5 mg polysorbate 80, 2.2 mg monobasic sodium phosphate, monohydrate, and 6.1 mg dibasic sodium phosphate, dihydrate. No preservatives are present.
CLINICAL PHARMACOLOGY

General

Infliximab neutralizes the biological activity of TNFα by binding with high affinity to the soluble and transmembrane forms of TNFα and inhibits binding of TNFα with its receptors. Infliximab does not neutralize TNFβ (lymphotoxin α), a related cytokine that utilizes the same receptors as TNFα. Biological activities attributed to TNFα include: induction of pro-inflammatory cytokines such as interleukins (IL) 1 and 6, enhancement of leukocyte migration by increasing endothelial layer permeability and expression of adhesion molecules by endothelial cells and leukocytes, activation of neutrophil and eosinophil functional activity, induction of acute phase reactants and other liver proteins, as well as tissue degrading enzymes produced by synoviocytes and/or chondrocytes. Cells expressing transmembrane TNFα bound by infliximab can be lysed in vitro or in vivo. Infliximab inhibits the functional activity of TNFα in a wide variety of in vitro bioassays utilizing human fibroblasts, endothelial cells, neutrophils, B and T lymphocytes and epithelial cells. Anti-TNFα antibodies reduce disease activity in the cotton-top tamarin colitis model, and decrease synovitis and joint erosions in a murine model of collagen-induced arthritis. Infliximab prevents disease in transgenic mice that develop polyarthritis as a result of constitutive expression of human TNFα, and when administered after disease onset, allows eroded joints to heal.

Pharmacodynamics

Elevated concentrations of TNFα have been found in involved tissues and fluids of patients with rheumatoid arthritis, Crohn’s disease, ulcerative colitis, ankylosing spondylitis and psoriatic arthritis. In rheumatoid arthritis, treatment with REMICADE reduced infiltration of inflammatory cells into inflamed areas of the joint as well as expression of molecules mediating cellular adhesion [E-selectin, intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1)], chemoattraction [IL-8 and monocyte chemotactic protein (MCP-1)] and tissue degradation [matrix metalloproteinase (MMP) 1 and 3]. In Crohn’s disease, treatment with REMICADE reduced infiltration of inflammatory cells and TNFα production in inflamed areas of the intestine, and reduced the proportion of mononuclear cells from the lamina propria able to express TNFα and interferon. After treatment with REMICADE, patients with rheumatoid arthritis or Crohn’s disease exhibited decreased levels of serum IL-6 and C-reactive protein (CRP) compared to baseline. Peripheral blood lymphocytes from REMICADE-treated patients showed no significant decrease in number or in proliferative responses to in vitro mitogenic stimulation when compared to cells from untreated patients. In psoriatic arthritis, treatment with REMICADE resulted in a reduction in the number of T-cells and blood vessels in the synovium and psoriatic skin as well as a reduction of macrophages in the synovium. The relationship between these pharmacodynamic activities and the mechanism(s) by which REMICADE exerts its clinical effects is unknown.
Pharmacokinetics

Single intravenous (IV) infusions of 3 mg/kg to 20 mg/kg showed a linear relationship between the dose administered and the maximum serum concentration. The volume of distribution at steady state was independent of dose and indicated that infliximab was distributed primarily within the vascular compartment. Pharmacokinetic results for doses of 3 mg/kg to 10 mg/kg in rheumatoid arthritis and 5 mg/kg in Crohn’s disease indicate that the median terminal half-life of infliximab is 8.0 to 9.5 days.

Following an initial dose of REMICADE, repeated infusions at 2 and 6 weeks resulted in predictable concentration-time profiles following each treatment. No systemic accumulation of infliximab occurred upon continued repeated treatment with 3 mg/kg or 10 mg/kg at 4- or 8-week intervals. Development of antibodies to infliximab increased infliximab clearance. At 8 weeks after a maintenance dose of 3 to 10 mg/kg of REMICADE, median infliximab serum concentrations ranged from approximately 0.5 to 6 mcg/mL; however, infliximab concentrations were not detectable (<0.1 mcg/mL) in patients who became positive for antibodies to infliximab.

No major differences in clearance or volume of distribution were observed in patient subgroups defined by age, weight, or gender. It is not known if there are differences in clearance or volume of distribution in patients with marked impairment of hepatic or renal function.

A pediatric Crohn’s disease pharmacokinetic study was conducted in 21 patients aged 11 to 17 years old. No notable differences in single-dose pharmacokinetic parameters were observed between pediatric and adult Crohn’s disease patients (see PRECAUTIONS, Pediatric Use).

CLINICAL STUDIES

Rheumatoid Arthritis

The safety and efficacy of REMICADE were assessed in two multicenter, randomized, double-blind, pivotal trials: ATTRACT (Study RA I) and ASPIRE (Study RA II). Concurrent use of stable doses of folic acid, oral corticosteroids (≤10 mg/day) and/or non-steroidal anti-inflammatory drugs was permitted.

Study RA I was a placebo-controlled study of 428 patients with active rheumatoid arthritis despite treatment with MTX. Patients enrolled had a median age of 54 years, median disease duration of 8.4 years, median swollen and tender joint count of 20 and 31 respectively, and were on a median dose of 15 mg/wk of MTX. Patients received either placebo + MTX or one of 4 doses/schedules of REMICADE + MTX: 3 mg/kg or 10 mg/kg of REMICADE by IV infusion at weeks 0, 2 and 6 followed by additional infusions every 4 or 8 weeks in combination with MTX.

Study RA II was a placebo-controlled study of three active treatment arms in 1004 MTX naive patients of 3 or fewer years duration active rheumatoid arthritis. Patients enrolled had a median age of 51 years with a median disease duration of 0.6 years, median swollen and tender joint count of 19 and 31, respectively, and >80% of patients had baseline joint erosions. At randomization, all patients received MTX (optimized to 20 mg/wk by week 8) and either placebo, 3mg/kg or 6 mg/kg REMICADE at weeks 0, 2, and 6 and every 8 weeks thereafter.
Data on use of REMICADE without concurrent MTX are limited (see ADVERSE REACTIONS, Immunogenicity).\textsuperscript{5,6}

Clinical response

In Study RA I, all doses/schedules of REMICADE + MTX resulted in improvement in signs and symptoms as measured by the American College of Rheumatology response criteria (ACR 20) with a higher percentage of patients achieving an ACR 20, 50 and 70 compared to placebo + MTX (Table 1). This improvement was observed at week 2 and maintained through week 102. Greater effects on each component of the ACR 20 were observed in all patients treated with REMICADE + MTX compared to placebo + MTX (Table 2). More patients treated with REMICADE reached a major clinical response than placebo-treated patients (Table 1).

In Study RA II, after 54 weeks of treatment, both doses of REMICADE + MTX resulted in statistically significantly greater response in signs and symptoms compared to MTX alone as measured by the proportion of patients achieving ACR 20, 50 and 70 responses (Table 1). More patients treated with REMICADE reached a major clinical response than placebo-treated patients (Table 1).
Table 1

ACR RESPONSE (PERCENT OF PATIENTS)

<table>
<thead>
<tr>
<th>Response</th>
<th>Study RA I</th>
<th></th>
<th>Study RA II</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>REMICADE + MTX</td>
<td></td>
<td>REMICADE + MTX</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>3 mg/kg</td>
<td>10 mg/kg</td>
<td>3 mg/kg</td>
<td>6 mg/kg</td>
<td></td>
</tr>
<tr>
<td></td>
<td>q 8 wks</td>
<td>q 4 wks</td>
<td>q 8 wks</td>
<td>q 4 wks</td>
<td></td>
</tr>
<tr>
<td></td>
<td>(n=88)</td>
<td>(n=86)</td>
<td>(n=87)</td>
<td>(n=81)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>(n=274)</td>
<td>(n=351)</td>
<td>(n=355)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ACR 20</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Week 30</td>
<td>20%</td>
<td>50%$^a$</td>
<td>52%$^a$</td>
<td>58%$^a$</td>
<td></td>
</tr>
<tr>
<td></td>
<td>50%$^a$</td>
<td>52%$^a$</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Week 54</td>
<td>17%</td>
<td>42%$^a$</td>
<td>59%$^a$</td>
<td>59%$^a$</td>
<td></td>
</tr>
<tr>
<td></td>
<td>48%$^a$</td>
<td>59%$^a$</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ACR 50</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Week 30</td>
<td>5%</td>
<td>27%$^a$</td>
<td>31%$^a$</td>
<td>26%$^a$</td>
<td></td>
</tr>
<tr>
<td></td>
<td>29%$^a$</td>
<td>31%$^a$</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Week 54</td>
<td>9%</td>
<td>21%$^c$</td>
<td>40%$^a$</td>
<td>38%$^a$</td>
<td></td>
</tr>
<tr>
<td></td>
<td>34%$^a$</td>
<td>40%$^a$</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ACR 70</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Week 30</td>
<td>0%</td>
<td>8%$^b$</td>
<td>18%$^a$</td>
<td>11%$^a$</td>
<td></td>
</tr>
<tr>
<td></td>
<td>11%$^b$</td>
<td>18%$^a$</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Week 54</td>
<td>2%</td>
<td>11%$^c$</td>
<td>26%$^a$</td>
<td>19%$^a$</td>
<td></td>
</tr>
<tr>
<td></td>
<td>18%$^a$</td>
<td>26%$^a$</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Major clinical response$^#$</td>
<td>0%</td>
<td>7%$^c$</td>
<td>15%$^a$</td>
<td>8%$^c$</td>
<td></td>
</tr>
<tr>
<td></td>
<td>8%$^b$</td>
<td>15%$^a$</td>
<td>6%$^c$</td>
<td>8%</td>
<td></td>
</tr>
</tbody>
</table>

$^#$ A major clinical response was defined as a 70% ACR response for 6 consecutive months (consecutive visits spanning at least 26 weeks) through week 102 for Study RA I and week 54 for Study RA II.

$^a p \leq 0.001$

$^b p < 0.01$

$^c p < 0.05$
### Table 2

**COMPONENTS OF ACR 20 AT BASELINE AND 54 WEEKS (Study RA I)**

<table>
<thead>
<tr>
<th>Parameter (medians)</th>
<th>Placebo + MTX (n=88)</th>
<th>REMICADE + MTX (n=340)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Baseline</td>
<td>Week 54</td>
</tr>
<tr>
<td>No. of Tender Joints</td>
<td>24</td>
<td>16</td>
</tr>
<tr>
<td>No. of Swollen Joints</td>
<td>19</td>
<td>13</td>
</tr>
<tr>
<td>Pain (^b)</td>
<td>6.7</td>
<td>6.1</td>
</tr>
<tr>
<td>Physician’s Global Assessment (^b)</td>
<td>6.5</td>
<td>5.2</td>
</tr>
<tr>
<td>Patient’s Global Assessment (^b)</td>
<td>6.2</td>
<td>6.2</td>
</tr>
<tr>
<td>Disability Index (HAQ-DI) (^c)</td>
<td>1.8</td>
<td>1.5</td>
</tr>
<tr>
<td>CRP (mg/dL)</td>
<td>3.0</td>
<td>2.3</td>
</tr>
</tbody>
</table>

\(^a\)All doses/schedules of REMICADE + MTX  
\(^b\)Visual Analog Scale (0=best, 10=worst)  
\(^c\)Health Assessment Questionnaire, measurement of 8 categories: dressing and grooming, arising, eating, walking, hygiene, reach, grip, and activities (0=best, 3=worst)

**Radiographic response**

Structural damage in both hands and feet was assessed radiographically at week 54 by the change from baseline in the van der Heijde-modified Sharp (vdH-S) score, a composite score of structural damage that measures the number and size of joint erosions and the degree of joint space narrowing in hands/wrists and feet.\(^7\)

In Study RA I, approximately 80% of patients had paired x-ray data at 54 weeks and approximately 70% at 102 weeks. The inhibition of progression of structural damage was observed at 54 weeks (Table 3) and maintained through 102 weeks.

In Study RA II, >90% of patients had at least two evaluable x-rays. Inhibition of progression of structural damage was observed at weeks 30 and 54 (Table 3) in the REMICADE + MTX groups compared to MTX alone. In an exploratory analysis of Study RA II, patients treated with REMICADE + MTX demonstrated less progression of structural damage compared to MTX alone, whether baseline acute phase reactants (ESR and CRP) were normal or elevated: patients with elevated baseline acute phase reactants treated with MTX alone demonstrated a mean progression in vdh-S score of 4.2 units compared to patients treated with REMICADE + MTX who demonstrated 0.5 units of progression; patients with normal baseline acute phase reactants...
treated with MTX alone demonstrated a mean progression in vdH-S score of 1.8 units compared to REMICADE + MTX who demonstrated 0.2 units of progression. Of patients receiving REMICADE + MTX, 59% had no progression (vdH-S score ≤ 0 unit) of structural damage compared to 45% patients receiving MTX alone. In a subset of patients who began the study without erosions, REMICADE + MTX maintained an erosion free state at 1 year in a greater proportion of patients than MTX alone, 79% (77/98) vs. 58% (23/40), respectively (p<0.01). Fewer patients in the REMICADE + MTX groups (47%) developed erosions in uninvolved joints compared to MTX alone (59%).
### Table 3
RADIOGRAPHIC CHANGE FROM BASELINE TO WEEK 54

<table>
<thead>
<tr>
<th>Study</th>
<th>Remicade + MTX</th>
<th>Placebo + MTX</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>3 mg/kg</td>
<td>10 mg/kg</td>
</tr>
<tr>
<td></td>
<td>q 8 wks</td>
<td>q 8 wks</td>
</tr>
<tr>
<td></td>
<td>(n=64)</td>
<td>(n=71)</td>
</tr>
</tbody>
</table>

**Total Score**

| | Baseline | Change from baseline |
| | Mean | Median | Mean | Median |
| Study RA I | 79 | 55 | 6.9 | 4.0 |
| Study RA II | 11.3 | 5.1 | 3.7 | 0.4 |

**Erosion Score**

| | Baseline | Change from baseline |
| | Mean | Median | Mean | Median |
| Study RA I | 44 | 25 | 4.1 | 2.0 |
| Study RA II | 8.3 | 3.0 | 3.0 | 0.3 |

**JSN Score**

| | Baseline | Change from baseline |
| | Mean | Median | Mean | Median |
| Study RA I | 36 | 26 | 2.9 | 1.5 |
| Study RA II | 3.0 | 1.0 | 0.6 | 0.0 |

^a P < 0.001 for each outcome against placebo.
Physical function response

Physical function and disability were assessed using the Health Assessment Questionnaire (HAQ-DI) and the general health-related quality of life questionnaire SF-36.

In Study RA I, all doses/schedules of REMI CADE + MTX showed significantly greater improvement from baseline in HAQ-DI and SF-36 physical component summary score averaged over time through week 54 compared to placebo + MTX, and no worsening in the SF-36 mental component summary score. The median (interquartile range) improvement from baseline to week 54 in HAQ-DI was 0.1 (-0.1, 0.5) for the placebo + MTX group and 0.4 (0.1, 0.9) for REMI CADE + MTX (p<0.001). Both HAQ-DI and SF-36 effects were maintained through week 102. Approximately 80% of patients in all doses/schedules of REMI CADE + MTX remained in the trial through 102 weeks.

In Study RA II, both REMI CADE treatment groups showed greater improvement in HAQ-DI from baseline averaged over time through week 54 compared to MTX alone; 0.7 for REMI CADE + MTX vs. 0.6 for MTX alone (p<0.001). No worsening in the SF-36 mental component summary score was observed.

Active Crohn’s Disease

The safety and efficacy of single and multiple doses of REMI CADE were assessed in two randomized, double-blind, placebo-controlled clinical studies in 653 patients with moderate to severely active Crohn’s disease [Crohn’s Disease Activity Index (CDAI) ≥220 and ≤400] with an inadequate response to prior conventional therapies. Concomitant stable doses of aminosalicylates, corticosteroids and/or immunomodulatory agents were permitted and 92% of patients continued to receive at least one of these medications.

In the single-dose trial of 108 patients, 16% (4/25) of placebo patients achieved a clinical response (decrease in CDAI ≥70 points) at week 4 vs. 81% (22/27) of patients receiving 5 mg/kg REMI CADE (p<0.001, two-sided, Fisher’s Exact test). Additionally, 4% (1/25) of placebo patients and 48% (13/27) of patients receiving 5 mg/kg REMI CADE achieved clinical remission (CDAI<150) at week 4.

In a multidose trial (ACCENT I [Study Crohn’s I]), 545 patients received 5 mg/kg at week 0 and were then randomized to one of three treatment groups; the placebo maintenance group received placebo at weeks 2 and 6, and then every 8 weeks; the 5 mg/kg maintenance group received 5 mg/kg at weeks 2 and 6, and then every 8 weeks; and the 10 mg/kg maintenance group received 5 mg/kg at weeks 2 and 6, and then 10 mg/kg every 8 weeks. Patients in response at week 2 were randomized and analyzed separately from those not in response at week 2. Corticosteroid taper was permitted after week 6.

At week 2, 57% (311/545) of patients were in clinical response. At week 30, a significantly greater proportion of these patients in the 5 mg/kg and 10 mg/kg maintenance groups achieved clinical remission compared to patients in the placebo maintenance group (Table 4).
Additionally, a significantly greater proportion of patients in the 5 mg/kg and 10 mg/kg REMICADE maintenance groups were in clinical remission and were able to discontinue corticosteroid use compared to patients in the placebo maintenance group at week 54 (Table 4).

### Table 4

**CLINICAL REMISSION AND STEROID WITHDRAWAL**

<table>
<thead>
<tr>
<th></th>
<th>Single 5 mg/kg Dose&lt;sup&gt;a&lt;/sup&gt;</th>
<th>Three Dose Induction&lt;sup&gt;b&lt;/sup&gt;</th>
<th>REMICADE Maintenance q 8 wks</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Placebo Maintenance</td>
<td>5 mg/kg</td>
<td>10 mg/kg</td>
</tr>
<tr>
<td>Week 30</td>
<td>25/102</td>
<td>41/104</td>
<td>48/105</td>
</tr>
<tr>
<td>Clinical remission</td>
<td>25%</td>
<td>39%</td>
<td>46%</td>
</tr>
<tr>
<td>p-value&lt;sup&gt;c&lt;/sup&gt;</td>
<td></td>
<td>0.022</td>
<td>0.001</td>
</tr>
<tr>
<td>Week 54</td>
<td>Patients in remission able to</td>
<td>6/54</td>
<td>14/56</td>
</tr>
<tr>
<td>discontinue corticosteroid use&lt;sup&gt;d&lt;/sup&gt;</td>
<td>11%</td>
<td>25%</td>
<td>34%</td>
</tr>
<tr>
<td>p-value&lt;sup&gt;c&lt;/sup&gt;</td>
<td></td>
<td>0.059</td>
<td>0.005</td>
</tr>
</tbody>
</table>

<sup>a</sup> REMICADE at week 0  
<sup>b</sup> REMICADE 5 mg/kg administered at weeks 0, 2 and 6  
<sup>c</sup> p-values represent pairwise comparisons to placebo  
<sup>d</sup> Of those receiving corticosteroids at baseline

Patients in the REMICADE maintenance groups (5 mg/kg and 10 mg/kg) had a longer time to loss of response than patients in the placebo maintenance group (Figure 1). At weeks 30 and 54, significant improvement from baseline was seen among the 5 mg/kg and 10 mg/kg REMICADE-treated groups compared to the placebo group in the disease specific inflammatory bowel disease questionnaire (IBDQ), particularly the bowel and systemic components, and in the physical component summary score of the general health-related quality of life questionnaire SF-36.
Compared to placebo maintenance:
Infliximab 10 mg/kg: p < 0.001
Infliximab 5 mg/kg: p = 0.004

Study Week

Patients Who had Not Lost Response (%)

Figure 1
Kaplan-Meier estimate of the proportion of patients who had not lost response through week 54

In a subset of 78 patients who had mucosal ulceration at baseline and who participated in an endoscopic substudy, 13 of 43 patients in the REMICADE maintenance group had endoscopic evidence of mucosal healing compared to 1 of 28 patients in the placebo group at week 10. Of the REMICADE-treated patients showing mucosal healing at week 10, 9 of 12 patients also showed mucosal healing at week 54.

Patients who achieved a response and subsequently lost response were eligible to receive REMICADE on an episodic basis at a dose that was 5 mg/kg higher than the dose to which they were randomized. The majority of such patients responded to the higher dose. Among patients who were not in response at week 2, 59% (92/157) of REMICADE maintenance patients responded by week 14 compared to 51% (39/77) of placebo maintenance patients. Among patients who did not respond by week 14, additional therapy did not result in significantly more responses (see DOSAGE AND ADMINISTRATION).

Fistulizing Crohn’s Disease

The safety and efficacy of REMICADE were assessed in 2 randomized, double-blind, placebo-controlled studies in patients with fistulizing Crohn’s disease with fistula(s) that were of at least 3 months duration. Concurrent use of stable doses of corticosteroids, 5-aminosalicylates, antibiotics, MTX, 6-mercaptopurine (6-MP) and/or azathioprine (AZA) was permitted.
In the first trial, 1094 patients received three doses of either placebo or REMICADE at weeks 0, 2 and 6. Fistula response (≥50% reduction in number of enterocutaneous fistulas draining upon gentle compression on at least two consecutive visits without an increase in medication or surgery for Crohn’s disease) was seen in 68% (21/31) of patients in the 5 mg/kg REMICADE group (p=0.002) and 56% (18/32) of patients in the 10 mg/kg REMICADE group (p=0.021) vs. 26% (8/31) of patients in the placebo arm. The median time to onset of response and median duration of response in REMICADE-treated patients was 2 and 12 weeks, respectively. Closure of all fistula was achieved in 52% of REMICADE-treated patients compared with 13% of placebo-treated patients (p<0.001).

In the second trial (ACCENT II [Study Crohn’s II]), patients who were enrolled had to have at least one draining enterocutaneous (perianal, abdominal) fistula. All patients received 5 mg/kg REMICADE at weeks 0, 2 and 6. Patients were randomized to placebo or 5 mg/kg REMICADE maintenance at week 14. Patients received maintenance doses at week 14 and then every eight weeks through week 46. Patients who were in fistula response (fistula response was defined the same as in the first trial) at both weeks 10 and 14 were randomized separately from those not in response. The primary endpoint was time from randomization to loss of response among those patients who were in fistula response.

Among the randomized patients (273 of the 296 initially enrolled), 87% had perianal fistulas and 14% had abdominal fistulas. Eight percent also had rectovaginal fistulas. Greater than 90% of the patients had received previous immunosuppressive and antibiotic therapy.

At week 14, 65% (177/273) of patients were in fistula response. Patients randomized to REMICADE maintenance had a longer time to loss of fistula response compared to the placebo maintenance group (Figure 2). At week 54, 38% (33/87) of REMICADE-treated patients had no draining fistulas compared with 22% (20/90) of placebo-treated patients (p=0.02). Compared to placebo maintenance, patients on REMICADE maintenance had a trend toward fewer hospitalizations.
Figure 2
Life table estimates of the proportion of patients who had not lost fistula response through week 54

Patients who achieved a fistula response and subsequently lost response were eligible to receive REMICADE maintenance therapy at a dose that was 5 mg/kg higher than the dose to which they were randomized. Of the placebo maintenance patients, 66% (25/38) responded to 5 mg/kg REMICADE, and 57% (12/21) of REMICADE maintenance patients responded to 10 mg/kg.

Patients who had not achieved a response by week 14 were unlikely to respond to additional doses of REMICADE.

Similar proportions of patients in either group developed new fistulas (17% overall) and similar numbers developed abscesses (15% overall).

Ankylosing Spondylitis

The safety and efficacy of REMICADE were assessed in a randomized, multicenter, double-blind, placebo-controlled study in 279 patients with active ankylosing spondylitis. Patients were between 18 and 74 years of age, and had ankylosing spondylitis as defined by the modified New York criteria for Ankylosing Spondylitis.11 Patients were to have had active disease as evidenced by both a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score >4 (possible range 0-10) and spinal pain >4 (on a Visual Analog Scale [VAS] of 0-10). Patients with complete ankylosis of the spine were excluded from study participation, and the use of Disease Modifying Anti-Rheumatic Drugs (DMARDs) and systemic corticosteroids were prohibited.
Doses of REMICADE 5 mg/kg or placebo were administered intravenously at Weeks 0, 2, 6, 12 and 18. At 24 weeks, improvement in the signs and symptoms of ankylosing spondylitis, as measured by the proportion of patients achieving a 20% improvement in ASAS response criteria (ASAS 20), was seen in 60% of patients in the REMICADE-treated group vs. 18% of patients in the placebo group (p<0.001). Improvement was observed at week 2 and maintained through week 24 (Figure 3 and Table 5).

![Proportion of patients achieving ASAS 20 response](image)

**Figure 3**
Proportion of patients achieving ASAS 20 response

At 24 weeks, the proportions of patients achieving a 50% and a 70% improvement in the signs and symptoms of ankylosing spondylitis, as measured by ASAS response criteria (ASAS 50 and ASAS 70, respectively), were 44% and 28%, respectively, for patients receiving REMICADE, compared to 9% and 4%, respectively, for patients receiving placebo (p<0.001, REMICADE vs. placebo). A low level of disease activity (defined as a value <20 [on a scale of 0-100 mm] in
each of the four ASAS response parameters) was achieved in 22% of REMICADE-treated patients vs. 1% in placebo-treated patients (p<0.001).

Table 5
Components of Ankylosing Spondylitis Disease Activity

<table>
<thead>
<tr>
<th></th>
<th>Placebo (n=78)</th>
<th>REMICADE 5mg/kg (n=201)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Baseline</td>
<td>Weeks</td>
</tr>
<tr>
<td>ASAS 20 response</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Criteria (Mean)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Patient global assessment(^a)</td>
<td>6.6</td>
<td>6.0</td>
</tr>
<tr>
<td>Spinal pain(^a)</td>
<td>7.3</td>
<td>6.5</td>
</tr>
<tr>
<td>BASFI(^b)</td>
<td>5.8</td>
<td>5.6</td>
</tr>
<tr>
<td>Inflammation(^c)</td>
<td>6.9</td>
<td>5.8</td>
</tr>
<tr>
<td>Acute Phase Reactants</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Median CRP(^d) (mg/dL)</td>
<td>1.7</td>
<td>1.5</td>
</tr>
<tr>
<td>Spinal Mobility (cm, Mean)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Modified Schober’s test(^e)</td>
<td>4.0</td>
<td>5.0</td>
</tr>
<tr>
<td>Chest expansion(^e)</td>
<td>3.6</td>
<td>3.7</td>
</tr>
<tr>
<td>Tragus to wall(^e)</td>
<td>17.3</td>
<td>17.4</td>
</tr>
<tr>
<td>Lateral spinal flexion(^e)</td>
<td>10.6</td>
<td>11.0</td>
</tr>
</tbody>
</table>

\(^a\) measured on a VAS with 0="none" and 10="severe"

\(^b\) Bath Ankylosing Spondylitis Functional Index (BASFI), average of 10 questions

\(^c\) Inflammation, average of last 2 questions on the 6 question BASDAI

\(^d\) CRP normal range 0-1.0 mg/dL

\(^e\) Spinal mobility normal values: modified Schober’s test: >4 cm; chest expansion:>6 cm; tragus to wall: <15 cm; lateral spinal flexion: >10 cm

The median improvement from baseline in the general health-related quality of life questionnaire SF-36 physical component summary score at week 24 was 10.2 for the REMICADE group vs. 0.8 for the placebo group (p<0.001). There was no change in the SF-36 mental component summary score in either the REMICADE group or the placebo group.

Results of this study were similar to those seen in a multicenter double-blind, placebo-controlled study of 70 patients with ankylosing spondylitis.

Psoriatic Arthritis

Safety and efficacy of REMICADE were assessed in a multicenter, double-blind, placebo-controlled study in 200 adult patients with active psoriatic arthritis despite DMARD or NSAID therapy (≥ 5 swollen joints and ≥ 5 tender joints) with one or more of the following subtypes: arthritis involving DIP joints (n = 49), arthritis mutilans (n = 3), asymmetric peripheral arthritis (n = 40), polyarticular arthritis (n = 100), and spondylitis with peripheral arthritis (n = 8).
Patients also had plaque psoriasis with a qualifying target lesion $\geq$ 2 cm in diameter. Forty-six percent of patients continued on stable doses of methotrexate ($\leq$ 25 mg/week). During the 24-week double-blind phase, patients received either 5 mg/kg REMICADE or placebo at weeks 0, 2, 6, 14, and 22 (100 patients in each group). At week 16, placebo patients with $< 10\%$ improvement from baseline in both swollen and tender joint counts were switched to REMICADE induction (early escape).

Treatment with REMICADE resulted in improvement in signs and symptoms, as assessed by the ACR criteria, with 58\% of REMICADE-treated patients achieving ACR 20 at week 14, compared with 11\% of placebo-treated patients ($p < 0.001$). The response was similar regardless of concomitant use of methotrexate. Improvement was observed as early as week 2. At 6 months, the ACR 20/50/70 responses were achieved by 54\%, 41\%, and 27\%, respectively, of patients receiving REMICADE compared to 16\%, 4\%, and 2\%, respectively, of patients receiving placebo. Similar responses were seen in patients with each of the subtypes of psoriatic arthritis, although few patients were enrolled with the arthritis mutilans and spondylitis with peripheral arthritis subtypes.

Compared to placebo, treatment with REMICADE resulted in improvements in the components of the ACR response criteria, as well as in dactylitis and enthesopathy (Table 6).

The results of this study were similar to those seen in an earlier multicenter, randomized, placebo-controlled study of 104 patients with psoriatic arthritis.

<p>| Table 6 |
| COMPONENTS OF ACR 20 AND PERCENTAGE OF PATIENTS WITH 1 OR MORE JOINTS WITH DACTYLITIS AND PERCENTAGE OF PATIENTS WITH ENTHESOPATHY |
| AT BASELINE and WEEK 24 |
| Parameter (medians) | Placebo (n=100) | REMICADE 5mg/kg&lt;sup&gt;a&lt;/sup&gt; (n=100) |
| No of Tender Joints&lt;sup&gt;b&lt;/sup&gt; | Baseline 24 | Week 24 20 | Baseline 20 | Week 24 6 |</p>
<table>
<thead>
<tr>
<th>No of Swollen Joints</th>
<th>12</th>
<th>9</th>
<th>12</th>
<th>3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pain</td>
<td>6.4</td>
<td>5.6</td>
<td>5.9</td>
<td>2.6</td>
</tr>
<tr>
<td>Physician’s Global Assessment</td>
<td>6.0</td>
<td>4.5</td>
<td>5.6</td>
<td>1.5</td>
</tr>
<tr>
<td>Patient’s Global Assessment</td>
<td>6.1</td>
<td>5.0</td>
<td>5.9</td>
<td>2.5</td>
</tr>
<tr>
<td>Disability Index (HAQ-DI)</td>
<td>1.1</td>
<td>1.1</td>
<td>1.1</td>
<td>0.5</td>
</tr>
<tr>
<td>CRP (mg/dL)</td>
<td>1.2</td>
<td>0.9</td>
<td>1.0</td>
<td>0.4</td>
</tr>
<tr>
<td>% Patients with 1 or more digits with dactylitis</td>
<td>41</td>
<td>33</td>
<td>40</td>
<td>15</td>
</tr>
<tr>
<td>% Patients with enthesopathy</td>
<td>35</td>
<td>36</td>
<td>42</td>
<td>22</td>
</tr>
</tbody>
</table>

a p<0.001 for percent change from baseline in all components of ACR 20 at week 24, p<0.05 for % of patients with dactylitis, and p=0.004 for % of patients with enthesopathy at week 24
b Scale 0-68
c Scale 0-66
d Visual Analog Scale (0=best, 10=worst)
e Health Assessment Questionnaire, measurement of 8 categories: dressing and grooming, arising, eating, walking, hygiene, reach, grip, and activities (0=best, 3=worst)
f Normal range 0-0.6 mg/dL

Improvement in PASI in patients with baseline body surface area (BSA) ≥ 3% (n=87 placebo, n=83 REMICADE) was achieved at week 14, regardless of concomitant methotrexate use, with 64% of REMICADE-treated patients achieving at least 75% improvement from baseline vs. 2% of placebo-treated patients; improvement was observed as early as week 2. At 6 months, the PASI 75 and PASI 90 responses were achieved by 60% and 39%, respectively, of patients receiving REMICADE compared to 1% and 0%, respectively, of patients receiving placebo.

**Ulcerative Colitis**

The safety and efficacy of REMICADE were assessed in two randomized, double-blind, placebo-controlled clinical studies in 728 patients with moderately to severely active ulcerative colitis (UC) (Mayo score ≥ 6 to 12 [of possible range 0-12], Endoscopy subscore ≥ 2) with an inadequate response to conventional oral therapies (Studies UC I and UC II). Concomitant treatment with stable doses of aminosalicylates, corticosteroids and/or immunomodulatory agents was permitted. Corticosteroid taper was permitted after week 8. In both studies, patients were randomized to receive either placebo, 5 mg/kg REMICADE or 10 mg/kg REMICADE at weeks 0, 2, 6, 14 and 22.

Patients in Study UC I had failed to respond or were intolerant to oral corticosteroids, 6-mercaptopurine (6-MP), or azathioprine (AZA). Patients in Study UC II had failed to respond or were intolerant to the above treatments and/or aminosalicylates. Similar proportions of patients in Studies UC I and UC II were receiving corticosteroids (61% and 51%, respectively), 6-MP/azathioprine (49% and 43%) and aminosalicylates (70% and 75%) at baseline. More patients in Study UC II than UC I were taking solely aminosalicylates for UC (26% vs. 11%,
respectively). Clinical response was defined as a decrease from baseline in the Mayo score by ≥ 30% and ≥ 3 points, accompanied by a decrease in the rectal bleeding subscore of ≥ 1 or a rectal bleeding subscore of 0 or 1.

In both studies, greater percentages of patients in both REMICADE groups achieved a clinical response, a sustained clinical response (response at both weeks 8 and 30), clinical remission and other assessed clinical outcomes than in the placebo group (Table 7). Of patients on corticosteroids at baseline, greater proportions of patients in the REMICADE treatment groups were in clinical remission and able to discontinue corticosteroids at week 30 compared with the patients in the placebo treatment groups (22% in REMICADE treatment groups vs. 10% in placebo group in Study UC I; 23% in REMICADE treatment groups vs. 3% in placebo group in Study UC II). The REMICADE-associated response was generally similar in the 5 mg/kg and 10 mg/kg dose groups.

Table 7  
Response, Remission and Mucosal Healing in Ulcerative Colitis Studies

<table>
<thead>
<tr>
<th>Patients randomized</th>
<th>Study UC I</th>
<th>Study UC II</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Placebo</td>
<td>5 mg/kg REMICADE</td>
</tr>
</tbody>
</table>
| Clinical Response
| Week 8    | 37% | 69%* | 62%* | 29% | 65%* | 69%* |
| Week 30   | 30% | 52%* | 51%** | 26% | 47%* | 60%* |
| Sustained Response
| (both Week 8 and 30) | 23% | 49%* | 46%* | 15% | 41%* | 53%* |
| Clinical Remission
| Week 8    | 15% | 39%* | 32%** | 6% | 34%* | 28%* |
| Week 30   | 16% | 34%* | 37%* | 11% | 26%** | 36%* |
| Sustained Remission
| (both Week 8 and 30) | 8% | 23%* | 26%* | 2% | 15%* | 23%* |
Mucosal Healing

<table>
<thead>
<tr>
<th>Week</th>
<th>Placebo</th>
<th>5 mg/kg</th>
<th>10 mg/kg</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>(n=121)</td>
<td>(n=121)</td>
<td>(n=122)</td>
</tr>
<tr>
<td>Stool frequency</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline</td>
<td>17%</td>
<td>17%</td>
<td>10%</td>
</tr>
<tr>
<td>Week 8</td>
<td>35%</td>
<td>60%</td>
<td>58%</td>
</tr>
<tr>
<td>Week 30</td>
<td>35%</td>
<td>51%</td>
<td>53%</td>
</tr>
<tr>
<td>Rectal Bleeding</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline</td>
<td>54%</td>
<td>40%</td>
<td>48%</td>
</tr>
<tr>
<td>Week 8</td>
<td>74%</td>
<td>86%</td>
<td>80%</td>
</tr>
<tr>
<td>Week 30</td>
<td>65%</td>
<td>74%</td>
<td>71%</td>
</tr>
<tr>
<td>Physician’s global assessment</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline</td>
<td>4%</td>
<td>6%</td>
<td>3%</td>
</tr>
<tr>
<td>Week 8</td>
<td>44%</td>
<td>74%</td>
<td>64%</td>
</tr>
<tr>
<td>Week 30</td>
<td>36%</td>
<td>57%</td>
<td>55%</td>
</tr>
<tr>
<td>Endoscopy findings</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline</td>
<td>0%</td>
<td>0%</td>
<td>0%</td>
</tr>
<tr>
<td>Week 8</td>
<td>34%</td>
<td>62%</td>
<td>59%</td>
</tr>
<tr>
<td>Week 30</td>
<td>26%</td>
<td>51%</td>
<td>52%</td>
</tr>
</tbody>
</table>

* P < 0.001, ** P < 0.01

1 Defined as a decrease from baseline in the Mayo score by ≥ 30% and ≥ 3 points, accompanied by a decrease in the rectal bleeding subscore of ≥ 1 or a rectal bleeding subscore of 0 or 1. (The Mayo score consists of the sum of four subscores: stool frequency, rectal bleeding, physician’s global assessment and endoscopy findings.)

2 Defined as a Mayo score ≤ 2 points, no individual subscore >1.

3 Defined as a 0 or 1 on the endoscopy subscore of the Mayo score.

The improvement with REMICADE was consistent across all Mayo subscores through week 30 (study UC I shown in Table 8; Study UC II was similar).
INDICATIONS AND USAGE

Rheumatoid Arthritis

REMICADE, in combination with methotrexate, is indicated for reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in patients with moderately to severely active rheumatoid arthritis.

Crohn’s Disease

REMICADE is indicated for reducing signs and symptoms and inducing and maintaining clinical remission in patients with moderately to severely active Crohn’s disease who have had an inadequate response to conventional therapy.

REMICADE is indicated for reducing the number of draining enterocutaneous and rectovaginal fistulas and maintaining fistula closure in patients with fistulizing Crohn’s disease.

Ankylosing Spondylitis

REMICADE is indicated for reducing signs and symptoms in patients with active ankylosing spondylitis.

Psoriatic Arthritis

REMICADE is indicated for reducing signs and symptoms of active arthritis in patients with psoriatic arthritis.

Ulcerative Colitis

REMICADE is indicated for reducing signs and symptoms, achieving clinical remission and mucosal healing, and eliminating corticosteroid use in patients with moderately to severely active ulcerative colitis who have had an inadequate response to conventional therapy.

CONTRAINDICATIONS

REMICADE at doses >5 mg/kg should not be administered to patients with moderate to severe heart failure. In a randomized study evaluating REMICADE in patients with moderate to severe heart failure (New York Heart Association [NYHA] Functional Class III/IV), REMICADE treatment at 10 mg/kg was associated with an increased incidence of death and hospitalization due to worsening heart failure (see WARNINGS and ADVERSE REACTIONS, Patients with Heart Failure).

REMICADE should not be administered to patients with known hypersensitivity to any murine proteins or other component of the product.
WARNINGS

RISK OF INFECTIONS
(See boxed WARNING)

Serious infections, including sepsis and pneumonia, have been reported in patients receiving TNF-blocking agents. Some of these infections have been fatal. Many of the serious infections in patients treated with Remicade have occurred in patients on concomitant immunosuppressive therapy that, in addition to their underlying disease, could predispose them to infections.

Remicade should not be given to patients with a clinically important, active infection. Caution should be exercised when considering the use of Remicade in patients with a chronic infection or a history of recurrent infection. Patients should be monitored for signs and symptoms of infection while on or after treatment with Remicade. New infections should be closely monitored. If a patient develops a serious infection, Remicade therapy should be discontinued (see Adverse Reactions, Infections).

Cases of tuberculosis, histoplasmosis, coccidioidomycosis, listeriosis, pneumocystosis, other bacterial, mycobacterial and fungal infections have been observed in patients receiving Remicade. For patients who have resided in regions where histoplasmosis or coccidioidomycosis is endemic, the benefits and risks of Remicade treatment should be carefully considered before initiation of Remicade therapy.

Serious infections were seen in clinical studies with concurrent use of anakinra and another TNF-α-blocking agent, etanercept, with no added clinical benefit compared to etanercept alone. Because of the nature of the adverse events seen with combination of etanercept and anakinra therapy, similar toxicities may also result from the combination of anakinra and other TNF-α-blocking agents. Therefore, the combination of Remicade and anakinra is not recommended.

Hepatotoxicity
Severe hepatic reactions, including acute liver failure, jaundice, hepatitis and cholestasis have been reported rarely in postmarketing data in patients receiving REMICADE. Autoimmune hepatitis has been diagnosed in some of these cases. Severe hepatic reactions occurred between two weeks to more than a year after initiation of REMICADE; elevations in hepatic aminotransferase levels were not noted prior to discovery of the liver injury in many of these cases. Some of these cases were fatal or necessitated liver transplantation. Patients with symptoms or signs of liver dysfunction should be evaluated for evidence of liver injury. If jaundice and/or marked liver enzyme elevations (e.g., ≥5 times the upper limit of normal) develops, REMICADE should be discontinued, and a thorough investigation of the abnormality should be undertaken. As with other immunosuppressive drugs, use of REMICADE has been associated with reactivation of hepatitis B in patients who are chronic carriers of this virus (i.e., surface antigen positive). Chronic carriers of hepatitis B should be appropriately evaluated and monitored prior to the initiation of and during treatment with REMICADE. In clinical trials, mild or moderate elevations of ALT and AST have been observed in patients receiving REMICADE without progression to severe hepatic injury (see ADVERSE REACTIONS, Hepatotoxicity).

Patients with Heart Failure

REMICADE has been associated with adverse outcomes in patients with heart failure, and should be used in patients with heart failure only after consideration of other treatment options. The results of a randomized study evaluating the use of REMICADE in patients with heart failure (NYHA Functional Class III/IV) suggested higher mortality in patients who received 10 mg/kg REMICADE, and higher rates of cardiovascular adverse events at doses of 5 mg/kg and 10 mg/kg. There have been post-marketing reports of worsening heart failure, with and without identifiable precipitating factors, in patients taking REMICADE. There have also been rare post-marketing reports of new onset heart failure, including heart failure in patients without known pre-existing cardiovascular disease. Some of these patients have been under 50 years of age. If a decision is made to administer REMICADE to patients with heart failure, they should be closely monitored during therapy, and REMICADE should be discontinued if new or worsening symptoms of heart failure appear. (See CONTRAINDICATIONS and ADVERSE REACTIONS, Patients with Heart Failure.)

Hematologic Events

Cases of leukopenia, neutropenia, thrombocytopenia, and pancytopenia, some with a fatal outcome, have been reported in patients receiving REMICADE. The causal relationship to REMICADE therapy remains unclear. Although no high-risk group(s) has been identified, caution should be exercised in patients being treated with REMICADE who have ongoing or a history of significant hematologic abnormalities. All patients should be advised to seek immediate medical attention if they develop signs and symptoms suggestive of blood dyscrasias or infection (e.g., persistent fever) while on REMICADE. Discontinuation of REMICADE therapy should be considered in patients who develop significant hematologic abnormalities.

Hypersensitivity
REMICADE has been associated with hypersensitivity reactions that vary in their time of onset and required hospitalization in some cases. Most hypersensitivity reactions, which include urticaria, dyspnea, and/or hypotension, have occurred during or within 2 hours of REMICADE infusion. However, in some cases, serum sickness-like reactions have been observed in Crohn’s disease patients 3 to 12 days after REMICADE therapy was reinstituted following an extended period without REMICADE treatment. Symptoms associated with these reactions include fever, rash, headache, sore throat, myalgias, polyarthralgias, hand and facial edema and/or dysphagia. These reactions were associated with marked increase in antibodies to infliximab, loss of detectable serum concentrations of infliximab, and possible loss of drug efficacy. REMICADE should be discontinued for severe reactions. Medications for the treatment of hypersensitivity reactions (e.g., acetaminophen, antihistamines, corticosteroids and/or epinephrine) should be available for immediate use in the event of a reaction (see ADVERSE REACTIONS, Infusion-related Reactions).

Neurologic Events

REMICADE and other agents that inhibit TNF have been associated in rare cases with optic neuritis, seizure and new onset or exacerbation of clinical symptoms and/or radiographic evidence of central nervous system demyelinating disorders, including multiple sclerosis, and CNS manifestation of systemic vasculitis. Prescribers should exercise caution in considering the use of REMICADE in patients with pre-existing or recent onset of central nervous system demyelinating or seizure disorders. Discontinuation of REMICADE should be considered in patients who develop significant central nervous system adverse reactions.

Malignancies

In the controlled portions of clinical trials of some TNF-blocking agents including REMICADE, more malignancies have been observed in patients receiving those TNF-blockers compared with control patients. During the controlled portions of REMICADE trials in patients with moderately to severely active rheumatoid arthritis, Crohn's disease, psoriatic arthritis, ankylosing spondylitis, and ulcerative colitis, 14 patients were diagnosed with malignancies among 2897 REMICADE-treated patients vs. 1 among 1262 control patients (at a rate of 0.65/100 patient-years among REMICADE-treated patients vs. a rate of 0.13/100 patient-years among control patients), with median duration of follow-up 0.5 years for REMICADE-treated patients and 0.4 years for control patients. Of these, the most common malignancies were breast, colorectal, and melanoma. The rate of malignancies among REMICADE-treated patients was similar to that expected in the general population whereas the rate in control patients was lower than expected.

In the controlled portions of clinical trials of all the TNF-blocking agents, more cases of lymphoma have been observed among patients receiving a TNF blocker compared with control patients. In the controlled and open-label portions of REMICADE clinical trials, 4 patients developed lymphomas among 4292 patients treated with REMICADE (median duration of follow-up 1.0 years) vs. 0 lymphomas in 1265 control patients (median duration of follow-up 0.5 years). In rheumatoid arthritis patients, 2 lymphomas were observed for a rate of 0.08 cases per
100 patient-years of follow-up, which is approximately 3-fold higher than expected in the general population. In the combined clinical trial population for rheumatoid arthritis, Crohn’s disease, psoriatic arthritis, ankylosing spondylitis, and ulcerative colitis, 4 lymphomas were observed for a rate of 0.11 cases per 100 patient-years of follow-up, which is approximately 5-fold higher than expected in the general population. Patients with Crohn's disease or rheumatoid arthritis, particularly patients with highly active disease and/or chronic exposure to immunosuppressant therapies, may be at a higher risk (up to several fold) than the general population for the development of lymphoma, even in the absence of TNF-blocking therapy.

The potential role of TNF-blocking therapy in the development of malignancies is not known (see ADVERSE REACTIONS, Malignancies). Rates in clinical trials for REMICADE cannot be compared to rates in clinical trials of other TNF-blockers and may not predict rates observed in a broader patient population. Caution should be exercised in considering REMICADE treatment in patients with a history of malignancy or in continuing treatment in patients who develop malignancy while receiving REMICADE.

PRECAUTIONS

Autoimmunity

Treatment with REMICADE may result in the formation of autoantibodies and, rarely, in the development of a lupus-like syndrome. If a patient develops symptoms suggestive of a lupus-like syndrome following treatment with REMICADE, treatment should be discontinued (see ADVERSE REACTIONS, Autoantibodies/Lupus-like Syndrome).

Vaccinations

No data are available on the response to vaccination with live vaccines or on the secondary transmission of infection by live vaccines in patients receiving anti-TNF therapy. It is recommended that live vaccines not be given concurrently.

Information for Patients

Patients should be provided the REMICADE Patient Information Sheet and provided an opportunity to read it prior to each treatment infusion session. Because caution should be exercised in administering REMICADE to patients with clinically important active infections, it is important that the patient's overall health be assessed at each treatment visit and any questions resulting from the patient's reading of the Patient Information Sheet be discussed.

Drug Interactions

Concurrent administration of etanercept (another TNF-α-blocking agent) and anakinra (an interleukin-1 antagonist) has been associated with an increased risk of serious infections, and increased risk of neutropenia and no additional benefit compared to these medicinal products
alone. Other TNFα-blocking agents (including REMICADE) used in combination with anakinra may also result in similar toxicities (see WARNINGS, RISK OF INFECTIONS).

Specific drug interaction studies, including interactions with MTX, have not been conducted. The majority of patients in rheumatoid arthritis or Crohn’s disease clinical studies received one or more concomitant medications. In rheumatoid arthritis, concomitant medications besides MTX were nonsteroidal anti-inflammatory agents, folic acid, corticosteroids and/or narcotics. Concomitant Crohn’s disease medications were antibiotics, antivirals, corticosteroids, 6-MP/AZA and aminosalicylates. In psoriatic arthritis clinical trials, concomitant medications included MTX in approximately half of the patients as well as nonsteroidal anti-inflammatory agents, folic acid and corticosteroids.

Patients with Crohn’s disease who received immunosuppressants tended to experience fewer infusion reactions compared to patients on no immunosuppressants (see ADVERSE REACTIONS, Immunogenicity and Infusion-related Reactions). Serum infliximab concentrations appeared to be unaffected by baseline use of medications for the treatment of Crohn’s disease including corticosteroids, antibiotics (metronidazole or ciprofloxacin) and aminosalicylates.

**Carcinogenesis, Mutagenesis and Impairment of Fertility**

A repeat dose toxicity study was conducted with mice given cV1q anti-mouse TNFα to evaluate tumorigenicity. CV1q is an analogous antibody that inhibits the function of TNFα in mice. Animals were assigned to 1 of 3 dose groups: control, 10 mg/kg or 40 mg/kg cV1q given weekly for 6 months. The weekly doses of 10 mg/kg and 40 mg/kg are 2 and 8 times, respectively, the human dose of 5 mg/kg for Crohn’s disease. Results indicated that cV1q did not cause tumorigenicity in mice. No clastogenic or mutagenic effects of infliximab were observed in the *in vivo* mouse micronucleus test or the *Salmonella-Escherichia coli* (Ames) assay, respectively. Chromosomal aberrations were not observed in an assay performed using human lymphocytes. The significance of these findings for human risk is unknown. It is not known whether infliximab can impair fertility in humans. No impairment of fertility was observed in a fertility and general reproduction toxicity study with the analogous mouse antibody used in the 6-month chronic toxicity study.
Pregnancy Category B

Since infliximab does not cross-react with TNFα in species other than humans and chimpanzees, animal reproduction studies have not been conducted with REMICADE. No evidence of maternal toxicity, embryotoxicity or teratogenicity was observed in a developmental toxicity study conducted in mice using an analogous antibody that selectively inhibits the functional activity of mouse TNFα. Doses of 10 to 15 mg/kg in pharmacodynamic animal models with the anti-TNF analogous antibody produced maximal pharmacologic effectiveness. Doses up to 40 mg/kg were shown to produce no adverse effects in animal reproduction studies. It is not known whether REMICADE can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. REMICADE should be given to a pregnant woman only if clearly needed.

Nursing Mothers

It is not known whether REMICADE is excreted in human milk or absorbed systemically after ingestion. Because many drugs and immunoglobulins are excreted in human milk, and because of the potential for adverse reactions in nursing infants from REMICADE, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.

Pediatric Use

Safety and effectiveness of REMICADE in patients with juvenile rheumatoid arthritis and in pediatric patients with Crohn’s disease or ulcerative colitis have not been established.

Geriatric Use

In rheumatoid arthritis clinical trials, no overall differences were observed in effectiveness or safety in 181 patients aged 65 or older compared to younger patients although the incidence of serious adverse events in patients aged 65 or older was higher in both REMICADE and control groups compared to younger patients. In Crohn’s disease, ulcerative colitis, ankylosing spondylitis and psoriatic arthritis studies, there were insufficient numbers of patients aged 65 and over to determine whether they respond differently from patients aged 18 to 65. Because there is a higher incidence of infections in the elderly population in general, caution should be used in treating the elderly (see ADVERSE REACTIONS, Infections).

ADVERSE REACTIONS

The data described herein reflect exposure to REMICADE in 3263 patients (1304 patients with rheumatoid arthritis, 1106 patients with Crohn’s disease, 202 with ankylosing spondylitis, 150 with psoriatic arthritis, 484 with ulcerative colitis and 17 patients with other conditions), including 1484 patients exposed beyond 30 weeks and 296 exposed beyond one year. The most common reason for discontinuation of treatment was infusion-related reactions (e.g. dyspnea, flushing, headache and rash). Adverse events have been reported in a higher proportion of
rheumatoid arthritis patients receiving the 10 mg/kg dose than the 3 mg/kg dose, however, no
differences were observed in the frequency of adverse events between the 5 mg/kg dose and 10
mg/kg dose in patients with Crohn’s disease.

**Infusion-related Reactions**

**Acute infusion reactions**

An infusion reaction was defined in clinical trials as any adverse event occurring during an
infusion or within 1 to 2 hours after an infusion. Approximately 20% of REMICADE-treated
patients in all clinical studies experienced an infusion reaction compared to approximately 10%
of placebo-treated patients. Among all REMICADE infusions, 3% were accompanied by
nonspecific symptoms such as fever or chills, 1% were accompanied by cardiopulmonary
reactions (primarily chest pain, hypotension, hypertension or dyspnea), and <1% were
accompanied by pruritus, urticaria, or the combined symptoms of pruritus/urticaria and
cardiopulmonary reactions. Serious infusion reactions occurred in <1% of patients and included
anaphylaxis, convulsions, erythematous rash and hypotension. Approximately 3% of patients
discontinued REMICADE because of infusion reactions, and all patients recovered with
treatment and/or discontinuation of the infusion. REMICADE infusions beyond the initial
infusion were not associated with a higher incidence of reactions.

Patients who became positive for antibodies to infliximab were more likely (approximately 2- to
3-fold) to have an infusion reaction than were those who were negative. Use of concomitant
immunosuppressant agents appeared to reduce the frequency of antibodies to infliximab and
infusion reactions (see ADVERSE REACTIONS, Immunogenicity and PRECAUTIONS, Drug
Interactions).

In post-marketing experience, cases of anaphylactic-like reactions, including
laryngeal/pharyngeal edema and severe bronchospasm, and seizure have been associated with
REMICADE administration.

**Reactions following readministration**

In a study where 37 of 41 patients with Crohn’s disease were retreated with infliximab following
a 2 to 4 year period without infliximab treatment, 10 patients experienced adverse events
manifesting 3 to 12 days following infusion of which 6 were considered serious. Signs and
symptoms included myalgia and/or arthralgia with fever and/or rash, with some patients also
experiencing pruritus, facial, hand or lip edema, dysphagia, urticaria, sore throat, and headache.
Patients experiencing these adverse events had not experienced infusion-related adverse events
associated with their initial infliximab therapy. These adverse events occurred in 39% (9/23) of
patients who had received liquid formulation which is no longer in use and 7% (1/14) of patients
who received lyophilized formulation. The clinical data are not adequate to determine if
occurrence of these reactions is due to differences in formulation. Patients’ signs and symptoms
improved substantially or resolved with treatment in all cases. There are insufficient data on the
incidence of these events after drug-free intervals of 1 to 2 years. These events have been
observed only infrequently in clinical studies and post-marketing surveillance with retreatment intervals up to 1 year.

**Infections**

In REMICADE clinical studies, treated infections were reported in 36% of REMICADE-treated patients (average of 51 weeks of follow-up) and in 25% of placebo-treated patients (average of 37 weeks of follow-up). The infections most frequently reported were respiratory tract infections (including sinusitis, pharyngitis, and bronchitis) and urinary tract infections. Among REMICADE-treated patients, serious infections included pneumonia, cellulitis, abscess, skin ulceration, sepsis, and bacterial infection. In clinical trials, 7 opportunistic infections were reported; 2 cases each of coccidioidomycosis (1 case was fatal) and histoplasmosis (1 case was fatal), and 1 case each of pneumocystosis, nocardiosis and cytomegalovirus. Tuberculosis was reported in 14 patients, 4 of whom died due to miliary tuberculosis. Other cases of tuberculosis, including disseminated tuberculosis, also have been reported post-marketing. Most of these cases of tuberculosis occurred within the first 2 months after initiation of therapy with REMICADE and may reflect recrudescence of latent disease (see WARNINGS, RISK OF INFECTIONS). In the 1 year placebo-controlled studies RA I and RA II, 5.3% of patients receiving REMICADE every 8 weeks with MTX developed serious infections as compared to 3.4% of placebo patients receiving MTX. Of 924 patients receiving REMICADE, 1.7% developed pneumonia and 0.4% developed TB, when compared to 0.3% and 0.0% in the placebo arm respectively. In a shorter (22-week) placebo-controlled study of 1082 RA patients randomized to receive placebo, 3 mg/kg or 10 mg/kg REMICADE infusions at 0, 2, and 6 weeks, followed by every 8 weeks with MTX, serious infections were more frequent in the 10 mg/kg REMICADE group (5.3%) than the 3 mg/kg or placebo groups (1.7% in both). During the 54 weeks Crohn’s II Study, 15% of patients with fistulizing Crohn’s disease developed a new fistula-related abscess.

In REMICADE clinical studies in patients with ulcerative colitis, infections treated with antimicrobials were reported in 19% of REMICADE-treated patients (average of 27 weeks of follow-up) and in 14% of placebo-treated patients (average 22 weeks of follow-up). The types of infections, including serious infections, reported in patients with ulcerative colitis were similar to those reported in other clinical studies.

In post-marketing experience, infections have been observed with various pathogens including viral, bacterial, fungal, and protozoal organisms. Infections have been noted in all organ systems and have been reported in patients receiving REMICADE alone or in combination with immunosuppressive agents.

**Autoantibodies/Lupus-like Syndrome**

Approximately half of REMICADE-treated patients in clinical trials who were antinuclear antibody (ANA) negative at baseline developed a positive ANA during the trial compared with approximately one-fifth of placebo-treated patients. Anti-dsDNA antibodies were newly detected in approximately one-fifth of REMICADE-treated patients compared with 0% of placebo-treated patients. Reports of lupus and lupus-like syndromes, however, remain uncommon.
Malignancies

In controlled trials, more REMICADE-treated patients developed malignancies than placebo-treated patients. (See WARNINGS, Malignancies.)

Malignancies, including non-Hodgkin’s lymphoma and Hodgkin’s disease, have also been reported in patients receiving REMICADE during post-approval use.

Patients with Heart Failure

In a randomized study evaluating REMICADE in moderate to severe heart failure (NYHA Class III/IV; left ventricular ejection fraction ≤35%), 150 patients were randomized to receive treatment with 3 infusions of REMICADE 10 mg/kg, 5 mg/kg, or placebo, at 0, 2, and 6 weeks. Higher incidences of mortality and hospitalization due to worsening heart failure were observed in patients receiving the 10 mg/kg REMICADE dose. At 1 year, 8 patients in the 10 mg/kg REMICADE group had died compared with 4 deaths each in the 5 mg/kg REMICADE and the placebo groups. There were trends towards increased dyspnea, hypotension, angina, and dizziness in both the 10 mg/kg and 5 mg/kg REMICADE treatment groups, versus placebo. REMICADE has not been studied in patients with mild heart failure (NYHA Class I/II). (See CONTRAINDICATIONS and WARNINGS, Patients with Heart Failure.)

Immunogenicity

Treatment with REMICADE can be associated with the development of antibodies to infliximab. The incidence of antibodies to infliximab in patients given a 3-dose induction regimen followed by maintenance dosing was approximately 10% as assessed through 1 to 2 years of REMICADE treatment. A higher incidence of antibodies to infliximab was observed in Crohn’s disease patients receiving REMICADE after drug free intervals >16 weeks. The majority of antibody-positive patients had low titers. Patients who were antibody-positive were more likely to have higher rates of clearance, reduced efficacy and to experience an infusion reaction (see ADVERSE REACTIONS, Infusion-related Reactions) than were patients who were antibody negative. Antibody development was lower among rheumatoid arthritis and Crohn’s disease patients receiving immunosuppressant therapies such as 6-MP/AZA or MTX.

The data reflect the percentage of patients whose test results were positive for antibodies to infliximab in an ELISA assay, and are highly dependent on the sensitivity and specificity of the assay. Additionally, the observed incidence of antibody positivity in an assay may be influenced by several factors including sample handling, timing of sample collection, concomitant medication, and underlying disease. For these reasons, comparison of the incidence of antibodies to infliximab with the incidence of antibodies to other products may be misleading.

Hepatotoxicity
Severe liver injury, including acute liver failure and autoimmune hepatitis, has been reported rarely in patients receiving REMICADE (see WARNINGS, Hepatotoxicity). Reactivation of hepatitis B has occurred in patients receiving REMICADE who are chronic carriers of this virus (i.e., surface antigen positive) (see WARNINGS, Hepatotoxicity).

In clinical trials in rheumatoid arthritis, Crohn’s disease, ulcerative colitis, ankylosing spondylitis and psoriatic arthritis, elevations of aminotransferases were observed (ALT more common than AST) in a greater proportion of patients receiving REMICADE than in controls (Table 9), both when REMICADE was given as monotherapy and when it was used in combination with other immunosuppressive agents. In general, patients who developed ALT and AST elevations were asymptomatic, and the abnormalities decreased or resolved with either continuation or discontinuation of REMICADE, or modification of concomitant medications.

### Table 9 Proportion of patients with elevated ALT in Clinical Trials

<table>
<thead>
<tr>
<th>Condition</th>
<th>Placebo</th>
<th>REMICADE</th>
<th>Placebo</th>
<th>REMICADE</th>
<th>Placebo</th>
<th>REMICADE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rheumatoid arthritis</td>
<td>24%</td>
<td>34%</td>
<td>3%</td>
<td>4%</td>
<td>&lt;1%</td>
<td>&lt;1%</td>
</tr>
<tr>
<td>Crohn’s disease</td>
<td>34%</td>
<td>39%</td>
<td>4%</td>
<td>5%</td>
<td>0%</td>
<td>2%</td>
</tr>
<tr>
<td>Ulcerative colitis</td>
<td>12%</td>
<td>15%</td>
<td>1%</td>
<td>2%</td>
<td>&lt;1%</td>
<td>&lt;1%</td>
</tr>
<tr>
<td>Ankylosing spondylitis</td>
<td>13%</td>
<td>40%</td>
<td>0%</td>
<td>6%</td>
<td>0%</td>
<td>2%</td>
</tr>
<tr>
<td>Psoriatic arthritis</td>
<td>16%</td>
<td>42%</td>
<td>0%</td>
<td>5%</td>
<td>0%</td>
<td>2%</td>
</tr>
</tbody>
</table>

1 Placebo patients received methotrexate while REMICADE patients received both REMICADE and methotrexate. Median follow-up was 58 weeks.

2 Placebo patients in the 2 Phase III trials in Crohn’s disease received an initial dose of 5 mg/kg REMICADE at study start and were on placebo in the maintenance phase. Patients who were randomized to the placebo maintenance group and then later crossed over to REMICADE are included in the REMICADE group in ALT analysis. Median follow-up was 54 weeks.

3 Median follow-up was 30 weeks.

4 Median follow-up was 24 weeks.

5 Median follow-up was 24 weeks for REMICADE group and 18 weeks for placebo group.

### Other Adverse Reactions

Safety data are available from 3263 REMICADE-treated patients, including 1304 with rheumatoid arthritis, 1106 with Crohn’s disease, 484 with ulcerative colitis, 202 with ankylosing spondylitis, 150 with psoriatic arthritis, and 17 with other conditions. Adverse events reported in ≥5% of all patients with rheumatoid arthritis receiving 4 or more infusions are in Table 10. The types and frequencies of adverse reactions observed were similar in REMICADE-treated
rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and Crohn's disease patients except for abdominal pain, which occurred in 26% of REMICADE-treated patients with Crohn's disease. In the Crohn's disease studies, there were insufficient numbers and duration of follow-up for patients who never received REMICADE to provide meaningful comparisons.

**Table 10**

**ADVERSE EVENTS OCCURRING IN 5% OR MORE OF PATIENTS RECEIVING 4 OR MORE INFUSIONS FOR RHEUMATOID ARTHRITIS**

<table>
<thead>
<tr>
<th>Event</th>
<th>Placebo (n=350)</th>
<th>REMICADE (n=1129)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Average weeks of follow-up</strong></td>
<td>59</td>
<td>66</td>
</tr>
<tr>
<td><strong>Gastrointestinal</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nausea</td>
<td>20%</td>
<td>21%</td>
</tr>
<tr>
<td>Abdominal Pain</td>
<td>8%</td>
<td>12%</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>12%</td>
<td>12%</td>
</tr>
<tr>
<td>Dyspepsia</td>
<td>7%</td>
<td>10%</td>
</tr>
<tr>
<td><strong>Respiratory</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Upper respiratory tract infection</td>
<td>25%</td>
<td>32%</td>
</tr>
<tr>
<td>Sinusitis</td>
<td>8%</td>
<td>14%</td>
</tr>
<tr>
<td>Pharyngitis</td>
<td>8%</td>
<td>12%</td>
</tr>
<tr>
<td>Coughing</td>
<td>8%</td>
<td>12%</td>
</tr>
<tr>
<td>Bronchitis</td>
<td>9%</td>
<td>10%</td>
</tr>
<tr>
<td>Rhinitis</td>
<td>5%</td>
<td>8%</td>
</tr>
<tr>
<td><strong>Skin and appendages disorders</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rash</td>
<td>5%</td>
<td>10%</td>
</tr>
<tr>
<td>Pruritus</td>
<td>2%</td>
<td>7%</td>
</tr>
<tr>
<td><strong>Body as a whole-general disorders</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fatigue</td>
<td>7%</td>
<td>9%</td>
</tr>
<tr>
<td>Pain</td>
<td>7%</td>
<td>8%</td>
</tr>
<tr>
<td><strong>Resistance mechanism disorders</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fever</td>
<td>4%</td>
<td>7%</td>
</tr>
<tr>
<td>Moniliasis</td>
<td>3%</td>
<td>5%</td>
</tr>
<tr>
<td><strong>Central and peripheral nervous system disorders</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Headache</td>
<td>14%</td>
<td>18%</td>
</tr>
<tr>
<td><strong>Musculoskeletal system disorders</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Back pain</td>
<td>5%</td>
<td>8%</td>
</tr>
<tr>
<td>Arthralgia</td>
<td>7%</td>
<td>8%</td>
</tr>
<tr>
<td><strong>Urinary system disorders</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Urinary tract infection</td>
<td>6%</td>
<td>8%</td>
</tr>
<tr>
<td><strong>Cardiovascular disorders, general</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hypertension</td>
<td>5%</td>
<td>7%</td>
</tr>
</tbody>
</table>
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in clinical trials of a drug cannot be directly compared to rates in clinical trials of another drug and may not predict the rates observed in broader patient populations in clinical practice.

The most common serious adverse events observed in clinical trials were infections (see ADVERSE REACTIONS, Infections). Other serious, medically relevant adverse events ≥0.2% or clinically significant adverse events by body system were as follows:

**Body as a whole:** allergic reaction, diaphragmatic hernia, edema, surgical/procedural sequela

**Blood:** pancytopenia

**Cardiovascular:** circulatory failure, hypotension, syncope

**Gastrointestinal:** constipation, gastrointestinal hemorrhage, ileus, intestinal obstruction, intestinal perforation, intestinal stenosis, pancreatitis, peritonitis, proctalgia

**Central & Peripheral Nervous:** meningitis, neuritis, peripheral neuropathy, dizziness

**Heart Rate and Rhythm:** arrhythmia, bradycardia, cardiac arrest, tachycardia

**Liver and Biliary:** biliary pain, cholecystitis, cholelithiasis, hepatitis

**Metabolic and Nutritional:** dehydration

**Musculoskeletal:** intervertebral disk herniation, tendon disorder

**Myo-, Endo-, Pericardial and Coronary Valve:** myocardial infarction

**Platelet, Bleeding and Clotting:** thrombocytopenia

**Neoplasms:** basal cell, breast, lymphoma

**Psychiatric:** confusion, suicide attempt

**Red Blood Cell:** anemia, hemolytic anemia

**Reproductive:** menstrual irregularity

**Resistance Mechanism:** cellulitis, sepsis, serum sickness

**Respiratory:** adult respiratory distress syndrome, lower respiratory tract infection (including pneumonia), pleural effusion, pleurisy, pulmonary edema, respiratory insufficiency

**Skin and Appendages:** increased sweating, ulceration

**Urinary:** renal calculus, renal failure

**Vascular (Extracardiac):** brain infarction, pulmonary embolism, thrombophlebitis

**White Cell and Reticuloendothelial:** leukopenia, lymphadenopathy

The following adverse events have been reported during post-approval use of REMICADE: neutropenia (see WARNINGS, Hematologic Events), interstitial pneumonitis/fibrosis, idiopathic thrombocytopenic purpura, thrombotic thrombocytopenic purpura, pericardial effusion, systemic and cutaneous vasculitis, Guillain-Barré syndrome, transverse myelitis, and neuropathies (additional neurologic events have also been observed, see WARNINGS, Neurologic Events). Because these events are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to REMICADE exposure.
OVERDOSAGE

Single doses up to 20 mg/kg have been administered without any direct toxic effect. In case of overdosage, it is recommended that the patient be monitored for any signs or symptoms of adverse reactions or effects and appropriate symptomatic treatment instituted immediately.

DOSAGE AND ADMINISTRATION

Rheumatoid Arthritis

The recommended dose of REMICADE is 3 mg/kg given as an intravenous infusion followed with additional similar doses at 2 and 6 weeks after the first infusion then every 8 weeks thereafter. REMICADE should be given in combination with methotrexate. For patients who have an incomplete response, consideration may be given to adjusting the dose up to 10 mg/kg or treating as often as every 4 weeks bearing in mind that risk of serious infections is increased at higher doses (see ADVERSE REACTIONS, Infections).

Crohn’s Disease or Fistulizing Crohn’s Disease

The recommended dose of REMICADE is 5 mg/kg given as an induction regimen at 0, 2 and 6 weeks followed by a maintenance regimen of 5 mg/kg every 8 weeks thereafter for the treatment of moderately to severely active Crohn’s disease or fistulizing disease. For patients who respond and then lose their response, consideration may be given to treatment with 10 mg/kg. Patients who do not respond by week 14 are unlikely to respond with continued dosing and consideration should be given to discontinue REMICADE in these patients.

Ankylosing Spondylitis

The recommended dose of REMICADE is 5 mg/kg given as an intravenous infusion followed with additional similar doses at 2 and 6 weeks after the first infusion, then every 6 weeks thereafter.

Psoriatic Arthritis

The recommended dose of REMICADE is 5 mg/kg given as an intravenous infusion followed with additional similar doses at 2 and 6 weeks after the first infusion then every 8 weeks thereafter. REMICADE can be used with or without methotrexate.

Ulcerative Colitis

The recommended dose of REMICADE is 5 mg/kg given as an induction regimen at 0, 2 and 6 weeks followed by a maintenance regimen of 5 mg/kg every 8 weeks thereafter for the treatment of moderately to severely active ulcerative colitis.
Preparation and Administration Instructions

Use aseptic technique.

REMIACA vials do not contain antibacterial preservatives. Therefore, the vials after reconstitution should be used immediately, not re-entered or stored. The diluent to be used for reconstitution is 10 mL of Sterile Water for Injection, USP. The total dose of the reconstituted product must be further diluted to 250 mL with 0.9% Sodium Chloride Injection, USP. The infusion concentration should range between 0.4 mg/mL and 4 mg/mL. The REMICADE infusion should begin within 3 hours of preparation.

1. Calculate the dose and the number of REMICADE vials needed. Each REMICADE vial contains 100 mg of infliximab. Calculate the total volume of reconstituted REMICADE solution required.

2. Reconstitute each REMICADE vial with 10 mL of Sterile Water for Injection, USP, using a syringe equipped with a 21-gauge or smaller needle. Remove the flip-top from the vial and wipe the top with an alcohol swab. Insert the syringe needle into the vial through the center of the rubber stopper and direct the stream of Sterile Water for Injection, USP, to the glass wall of the vial. Do not use the vial if the vacuum is not present. Gently swirl the solution by rotating the vial to dissolve the lyophilized powder. Avoid prolonged or vigorous agitation. DO NOT SHAKE. Foaming of the solution on reconstitution is not unusual. Allow the reconstituted solution to stand for 5 minutes. The solution should be colorless to light yellow and opalescent, and the solution may develop a few translucent particles as infliximab is a protein. Do not use if opaque particles, discoloration, or other foreign particles are present.

3. Dilute the total volume of the reconstituted REMICADE solution dose to 250 mL with 0.9% Sodium Chloride Injection, USP, by withdrawing a volume of 0.9% Sodium Chloride Injection, USP, equal to the volume of reconstituted REMICADE from the 0.9% Sodium Chloride Injection, USP, 250 mL bottle or bag. Slowly add the total volume of reconstituted REMICADE solution to the 250 mL infusion bottle or bag. Gently mix.

4. The infusion solution must be administered over a period of not less than 2 hours and must use an infusion set with an in-line, sterile, non-pyrogenic, low-protein-binding filter (pore size of 1.2 µm or less). Any unused portion of the infusion solution should not be stored for reuse.

5. No physical biochemical compatibility studies have been conducted to evaluate the co-administration of REMICADE with other agents. REMICADE should not be infused concomitantly in the same intravenous line with other agents.

6. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. If visibly opaque particles, discoloration or other foreign particulates are observed, the solution should not be used.
Storage

Store the lyophilized product under refrigeration at 2°C to 8°C (36°F to 46°F). Do not freeze. Do not use beyond the expiration date. This product contains no preservative.

HOW SUPPLIED

REMICADE lyophilized concentrate for IV injection is supplied in individually-boxed single-use vials in the following strength:

NDC 57894-030-01  100 mg infliximab in a 20 mL vial

REFERENCES


©Centocor, Inc. 2005

Malvern, PA 19355, USA

License #1242

1-800-457-6399

Revised September 2005
Rx Only

REMICADE® (infliximab)
Patient Information Sheet

You should read this information sheet before you start using REMICADE® (pronounced rem-eh-kaid) and before each time you are scheduled to receive REMICADE. This information sheet does not take the place of talking with your doctor. You and your doctor should talk about your health and how you are feeling before you start taking REMICADE, while you are taking it and at regular checkups. If you do not understand any of the information in this sheet, you should ask your doctor to explain what it means.

What is REMICADE?
REMICADE is a medicine that is used to treat adults with moderately to severely active rheumatoid arthritis, Crohn’s disease and ulcerative colitis. In Crohn’s disease and ulcerative colitis, REMICADE is for people who have not responded well enough to other medicines. REMICADE is also used to treat active ankylosing spondylitis and psoriatic arthritis.

How does REMICADE work?
The medicine REMICADE is a type of protein that recognizes, attaches to and blocks the action of a substance in your body called tumor necrosis factor. Tumor necrosis factor (TNF) is made by certain blood cells in your body. REMICADE will not cure rheumatoid arthritis, Crohn’s disease, ulcerative colitis, ankylosing spondylitis or psoriatic arthritis, but blocking TNF with REMICADE may reduce the inflammation caused by TNF in your body. You should also know that REMICADE may help you feel better but can also cause serious side effects and can reduce your body’s ability to fight infections (see below).

What should I know about the immune system, and taking REMICADE for Rheumatoid Arthritis, Crohn’s Disease, Ulcerative Colitis, Ankylosing Spondylitis or Psoriatic Arthritis?
The immune system protects the body by responding to “invaders” like bacteria, viruses and other foreign matter that enter your body by producing antibodies and putting them into action to fight off the “invaders.” In diseases like rheumatoid arthritis, Crohn’s disease, ulcerative colitis, ankylosing spondylitis and psoriatic arthritis, TNF can cause your immune system to attack healthy tissues in your body and cause inflammation and damage. If these diseases are untreated, it can cause permanent damage to the body’s bones, cartilage and tissue.

While taking REMICADE can block the TNF that causes inflammation, it can also lower your body’s ability to fight infections. So, taking REMICADE can make you more prone to getting infections or it can make an infection that you already have worse. You should call your doctor right away if you think you have an infection.

What important information should I know about treatment with REMICADE?
REMICADE, like other medicines that affect your immune system, is a strong medicine that can cause serious side effects. Possible serious side effects include:
Serious Infections:

- Some patients have had serious infections while receiving REMICADE. Some of the patients have died from these infections. Serious infections include TB (tuberculosis), and infections caused by viruses, fungi or bacteria that have spread throughout the body. If you develop a fever, feel very tired, have a cough, or have flu-like symptoms, these could be signs that you may be getting an infection. If you have any of these symptoms while you are taking or after you have taken REMICADE, you should tell your doctor right away.

Heart Failure:

- If you have been told that you have a heart problem called congestive heart failure and you are currently being treated with REMICADE, you will need to be closely monitored by your doctor. If you develop new or worse symptoms that are related to your heart condition, such as shortness of breath or swelling of your ankles or feet, you must contact your doctor immediately.

Blood Problems:

- In some patients the body may fail to produce enough of the blood cells that help your body fight infections or help you stop bleeding. Some of the patients have died from this failure to produce blood cells. If you develop a fever that doesn't go away, bruise or bleed very easily or look very pale, call your doctor right away. Your doctor may decide to stop your treatment.

Allergic Reactions:

- Some patients have had severe allergic reactions to REMICADE. These reactions can happen while you are getting your REMICADE infusion or shortly afterwards. The symptoms of an allergic reaction may include hives (red, raised, itchy patches of skin), difficulty breathing, chest pain and high or low blood pressure. Your doctor may decide to stop REMICADE treatment and give you medicines to treat the allergic reaction.

- Some patients who have been taking REMICADE for Crohn’s disease have had allergic reactions 3 to 12 days after receiving their REMICADE treatment. The symptoms of this type of delayed reaction may include fever, rash, headache and muscle or joint pain. Call your doctor right away if you develop any of these symptoms or any other unusual symptoms such as difficulty swallowing.

Nervous System Disorders:

- There have been rare cases where people taking REMICADE or other TNF blockers have developed disorders that affected their nervous system. Signs that you could be having a problem include: changes in your vision, weakness in your arms and/or legs, and numbness or tingling in any part of your body.

Cancer:

- Reports of a type of blood cancer called lymphoma in patients on REMICADE or other TNF blockers are rare but occur more often than expected for people in general. People who have been treated for rheumatoid arthritis, Crohn’s disease, ankylosing spondylitis or psoriatic arthritis for a long time, particularly those with highly active disease may be more prone to
develop lymphoma. Cancers, other than lymphoma, have also been reported. If you take REMICADE or other TNF blockers, your risk for developing lymphoma or other cancers may increase. You should also tell your doctor if you have had or develop lymphoma or other cancers while you are taking REMICADE.

Liver Injury:

• There have been rare cases where people taking REMICADE have developed serious liver problems, some fatal. Signs that you could be having a problem include: jaundice (skin and eyes turning yellow), dark brown-colored urine, right sided abdominal pain, fever, and severe fatigue (tiredness). You should contact your doctor immediately if you develop any of these symptoms.

Other Important Information

Some patients have developed symptoms that can resemble a disease called lupus. Lupus-like symptoms may include chest discomfort or pain that doesn’t go away, shortness of breath, joint pain, or a rash on the cheeks or arms that gets worse in the sun. If you develop any of these symptoms your doctor may decide to stop your treatment with REMICADE.

What are the more common side effects of REMICADE?
The more common side effects with REMICADE are respiratory infections (that may include sinus infections and sore throat), coughing and stomach pain.

Who should not take REMICADE?

YOU SHOULD NOT take REMICADE if you have:

• Heart failure, unless your doctor has talked to you and decided that you are able to take REMICADE.
• Had an allergic reaction to REMICADE or any other product that was made with murine (mouse) proteins.

What health concerns should I talk to my doctor about?

Before receiving your first treatment with REMICADE you should tell your doctor if you:

• Have or think you may have any kind of infection. The infection could be in only one place in your body (such as an open cut or sore), or an infection that affects your whole body (such as the flu). Having an infection could put you at risk for serious side effects from REMICADE.
• Have an infection that won’t go away or a history of infection that keeps coming back.
• Have had TB (tuberculosis), or if you have recently been with anyone who might have TB. Your doctor will examine you for TB and perform a skin test. If your doctor feels that you are at risk for TB, he or she may start treating you for TB before you begin REMICADE therapy.
• Have lived in or visited an area of the country where an infection called histoplasmosis or coccidioidomycosis (an infection caused by a fungus that affects the lungs) is common. If you don’t know if the area you live in is one where histoplasmosis or coccidioidomycosis is common, ask your doctor.
• Have or have previously had heart failure or other heart conditions.
• Have or have had a condition that affects your nervous system, like multiple sclerosis, or Guillain-Barré syndrome, or if you experience any numbness, or tingling, or have had a seizure.
• Are pregnant or nursing.
• Have recently received or are scheduled to receive a vaccine.

Can I take REMICADE while I am on other medicines?
Tell your doctor if you are taking any other medicines including over the counter medicines, supplements or herbal products before you are treated with REMICADE. If you start taking or plan to start taking any new medicine while you are taking REMICADE, tell your doctor.
REMICADE and KINERET should not be taken together.

How will REMICADE be given to me?
REMICADE will be given to you by a healthcare professional. REMICADE will be given to you by an IV. This means that the medicine will be given to you through a needle placed in a vein in your arm. It will take about 2 hours to give you the full dose of medicine. During that time and for a period after you receive REMICADE, you will be monitored by a healthcare professional. Your doctor may ask you to take other medicines along with REMICADE.
Only a health care professional should prepare the medicine and administer it to you.

How often will I receive REMICADE?
Rheumatoid Arthritis
If you are receiving REMICADE for rheumatoid arthritis you will receive your first dose followed by additional doses at 2 and 6 weeks after the first dose. You will then receive a dose every 8 weeks. Your doctor will monitor your response to REMICADE and may change your dose or treat you more frequently (as often as every 4 weeks).

Crohn’s Disease or Fistulizing Crohn’s Disease
If you are receiving REMICADE for active Crohn's disease or fistulizing Crohn’s disease, you will receive your first dose followed by additional doses at 2 and 6 weeks after the first dose. You will then receive a dose every 8 weeks. Your doctor will monitor your response to REMICADE and may change your dose.

Ulcerative Colitis
If you are receiving REMICADE for ulcerative colitis, you will receive your first dose followed by additional doses at 2 and 6 weeks after the first dose. You will then receive a dose every 8 weeks and your doctor will monitor your response to REMICADE.

Ankylosing Spondylitis
If you are receiving REMICADE for ankylosing spondylitis you will receive your first dose followed by additional doses at 2 and 6 weeks after the first dose. You will then receive a dose every 6 weeks.
Psoriatic Arthritis

If you are receiving REMICADE for psoriatic arthritis you will receive your first dose followed by additional doses at 2 and 6 weeks after the first dose. You will then receive a dose every 8 weeks.

**What if I still have questions?**

If you have any questions, or problems, always talk first with your doctor. You can also visit the REMICADE internet site at [www.remicade.com](http://www.remicade.com).

Product developed and manufactured by:

Centocor, Inc.

200 Great Valley Parkway

Malvern, PA 19355

Revised September 2005